Two Sigma Advisers LP lowered its position in shares of Alkermes plc (NASDAQ:ALKS - Free Report) by 67.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 20,700 shares of the company's stock after selling 42,203 shares during the quarter. Two Sigma Advisers LP's holdings in Alkermes were worth $595,000 at the end of the most recent quarter.
Several other large investors have also bought and sold shares of the company. Stempoint Capital LP boosted its stake in Alkermes by 752.4% during the fourth quarter. Stempoint Capital LP now owns 416,968 shares of the company's stock valued at $11,992,000 after buying an additional 368,050 shares in the last quarter. RTW Investments LP increased its stake in Alkermes by 13.6% in the 4th quarter. RTW Investments LP now owns 7,557,835 shares of the company's stock worth $217,363,000 after purchasing an additional 903,802 shares in the last quarter. ProShare Advisors LLC increased its stake in Alkermes by 27.9% in the 4th quarter. ProShare Advisors LLC now owns 56,211 shares of the company's stock worth $1,617,000 after purchasing an additional 12,274 shares in the last quarter. Quantedge Capital Pte Ltd purchased a new position in Alkermes in the 4th quarter worth about $1,665,000. Finally, Quantinno Capital Management LP purchased a new position in Alkermes in the 4th quarter worth about $247,000. Institutional investors own 95.21% of the company's stock.
Alkermes Stock Up 2.3%
Shares of ALKS traded up $0.71 during midday trading on Friday, reaching $31.71. 1,125,369 shares of the stock were exchanged, compared to its average volume of 1,742,562. Alkermes plc has a 12-month low of $22.90 and a 12-month high of $36.45. The firm has a 50 day simple moving average of $29.62 and a 200-day simple moving average of $30.94. The company has a market cap of $5.23 billion, a price-to-earnings ratio of 14.61, a P/E/G ratio of 2.20 and a beta of 0.47.
Alkermes (NASDAQ:ALKS - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported $0.13 earnings per share for the quarter, missing analysts' consensus estimates of $0.32 by ($0.19). Alkermes had a return on equity of 30.80% and a net margin of 23.57%. The firm had revenue of $306.51 million for the quarter, compared to analysts' expectations of $307.53 million. During the same period last year, the business earned $0.43 earnings per share. The firm's revenue for the quarter was down 12.6% on a year-over-year basis. Research analysts expect that Alkermes plc will post 1.31 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of equities analysts recently weighed in on ALKS shares. The Goldman Sachs Group lifted their price target on Alkermes from $30.00 to $32.00 and gave the stock a "buy" rating in a research note on Friday, February 14th. Royal Bank of Canada lifted their price target on Alkermes from $39.00 to $40.00 and gave the stock a "sector perform" rating in a research note on Friday, May 2nd. Robert W. Baird raised their price objective on Alkermes from $38.00 to $41.00 and gave the stock an "outperform" rating in a research report on Friday, May 2nd. UBS Group restated a "sector perform" rating on shares of Alkermes in a research report on Monday, April 28th. Finally, Wall Street Zen lowered Alkermes from a "strong-buy" rating to a "buy" rating in a research report on Monday, May 5th. Four analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Alkermes currently has a consensus rating of "Moderate Buy" and a consensus target price of $38.85.
View Our Latest Research Report on ALKS
About Alkermes
(
Free Report)
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Further Reading
Before you consider Alkermes, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alkermes wasn't on the list.
While Alkermes currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
